aTyr Pharma holds less than 2% of cash at failed SVB; exposure limited

aTYR PHARMA INC

As of March 10, 2023, aTyr holds less than 2% of cash equivalents and investments at SVB.
Company acknowledges SVB closure and FDIC receivership in SEC filing.
Remaining >98% of cash is held at other institutions, minimizing direct risk.
No material financial or operational impact anticipated from SVB failure.
Disclosure made under Regulation FD on March 10, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.